Latest News

Exclusive Interviews

Browse by Company

  • All
  • AIkido Pharma
  • Aion Therapeutic
  • Albert Labs
  • Aleafia Health
  • Algernon Pharmaceuticals
  • Alphamind
  • Atai Life Sciences
  • Atma Journeys
  • AWAKN
  • Beckley Psytech
  • Better Plant Sciences
  • BetterLife Pharma
  • Bright Minds Biosciences
  • Brightmind
  • Buzz Capital
  • CaaMTech
  • CannaGlobal Wellness
  • CB Therapeutics
  • CBDV
  • Champignon Brands
  • Compass Pathways
  • Cybin Corp
  • Delic Corp
  • DemeRx
  • Diamond Therapeutics
  • Ehave
  • Ei Foundation
  • Ei Ventures
  • Eleusian Biosciences
  • Eleusis
  • Empower Clinics
  • Entheon Biomedical
  • Entheos Foundation
  • Field Trip Health
  • GreenStar Biosciences
  • Havn Life
  • Hollister Biosciences
  • Liberty Leaf
  • Lobe Sciences
  • MagicMed
  • MAPS
  • Mind Cure
  • Mindleap
  • MindMed
  • Mindset Pharma
  • Mota Ventures
  • Mydecine
  • NeonMind
  • New Wave
  • NewLeaf Brands
  • Noetic Foundry
  • Nova Mentis
  • Nova Mentis Biotech
  • Novamind
  • Numinus
  • Nutritional High
  • NYU Langone Health
  • Octarine Bio
  • Optimi Health
  • Orthogonal Thinker
  • Osmond Labs
  • Osoyoos
  • Pharmadrug
  • Pharmather
  • Pilz Bioscience
  • PSFC
  • Psilera Bioscience
  • PsyBio
  • Psyched Wellness
  • Psyence Group
  • Psygen
  • PSYK
  • Pure Extracts
  • Red Light Holland
  • Revive Therapeutics
  • Silo Pharma
  • Silo Wellness
  • Small Pharma
  • SYNTAC Institute
  • Synthesis Institute
  • The Lundquist Institute
  • TheraPsil
  • Thoughtful Brands
  • Tryp Therapeutics
  • Unlimited Sciences
  • Usona Institute
  • Wesana Health
  • Wuhan General Group
  • Yield Growth Corp
All
  • All
  • AIkido Pharma
  • Aion Therapeutic
  • Albert Labs
  • Aleafia Health
  • Algernon Pharmaceuticals
  • Alphamind
  • Atai Life Sciences
  • Atma Journeys
  • AWAKN
  • Beckley Psytech
  • Better Plant Sciences
  • BetterLife Pharma
  • Bright Minds Biosciences
  • Brightmind
  • Buzz Capital
  • CaaMTech
  • CannaGlobal Wellness
  • CB Therapeutics
  • CBDV
  • Champignon Brands
  • Compass Pathways
  • Cybin Corp
  • Delic Corp
  • DemeRx
  • Diamond Therapeutics
  • Ehave
  • Ei Foundation
  • Ei Ventures
  • Eleusian Biosciences
  • Eleusis
  • Empower Clinics
  • Entheon Biomedical
  • Entheos Foundation
  • Field Trip Health
  • GreenStar Biosciences
  • Havn Life
  • Hollister Biosciences
  • Liberty Leaf
  • Lobe Sciences
  • MagicMed
  • MAPS
  • Mind Cure
  • Mindleap
  • MindMed
  • Mindset Pharma
  • Mota Ventures
  • Mydecine
  • NeonMind
  • New Wave
  • NewLeaf Brands
  • Noetic Foundry
  • Nova Mentis
  • Nova Mentis Biotech
  • Novamind
  • Numinus
  • Nutritional High
  • NYU Langone Health
  • Octarine Bio
  • Optimi Health
  • Orthogonal Thinker
  • Osmond Labs
  • Osoyoos
  • Pharmadrug
  • Pharmather
  • Pilz Bioscience
  • PSFC
  • Psilera Bioscience
  • PsyBio
  • Psyched Wellness
  • Psyence Group
  • Psygen
  • PSYK
  • Pure Extracts
  • Red Light Holland
  • Revive Therapeutics
  • Silo Pharma
  • Silo Wellness
  • Small Pharma
  • SYNTAC Institute
  • Synthesis Institute
  • The Lundquist Institute
  • TheraPsil
  • Thoughtful Brands
  • Tryp Therapeutics
  • Unlimited Sciences
  • Usona Institute
  • Wesana Health
  • Wuhan General Group
  • Yield Growth Corp
Weekly Psychedelic Bulletin
Psychedelic Investment Bulletin

Psychedelic Bulletin: CA Decrim. Bill Passes Key Committee; MindMed Publishes MDMA Dosing Study; atai Acquires DTx Company

BetterLife Pharma News
Press Release

Former FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory Advisor

Mind Cure Psychedelic Company
Press Release

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

Psychedelic Research Bulletin
Psychedelics Research Review

Psychedelic Research Bulletin: March 2021

ATAI Life Sciences Press Release
Press Release

atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders

Silo Pharma Press Release
Press Release

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

Mydecine Press Release
Press Release

Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical

Lobe Sciences PR
Press Release

Lobe Sciences Appoints Ilan Hayman to Advisory Board